Goldman Sachs Upgrades Taysha Gene Therapies on Rett Syndrome Potential
Goldman Sachs upgrades Taysha Gene Therapies to Buy with an $11 target, citing strong confidence in the company’s Rett syndrome program and REVEAL study expectations.
Goldman Sachs upgrades Taysha Gene Therapies to Buy with an $11 target, citing strong confidence in the company’s Rett syndrome program and REVEAL study expectations.
A look at why analysts are favoring Neurogene over Taysha in the race for gene therapy approvals, focusing on study design, FDA alignment, and long-term patient outcomes.
The FDA has granted Breakthrough Therapy designation to TSHA-102 for Rett Syndrome, acknowledging its potential to redefine treatment.